Sector News

Russia suggests creating green corridor for pharmaceutical companies – deputy PM

March 27, 2018
Life sciences

Moscow has suggested to Tokyo that a green corridor be created for pharmaceutical companies, Russian Deputy Prime Minister Olga Golodets said ahead of a meeting with Japan’s Minister of Economy, Trade and Industry Hiroshige Seko on Saturday.

“We have suggested that the so-called green corridor be created for pharmaceutical companies, as we want to ease the access to the Russian market for Japanese companies,” she said, adding that talks on that matter have been held with Hitachi, Ltd.

The meeting also involves Russian Economic Development Minister Maksim Oreshkin.

Moscow and Tokyo have been have been boosting economic cooperation based on the Japanese prime minister’s eight-point plan. The document stipulates that Russia and Japan should strengthen relations in the energy sphere, small and medium-size business, the industrialization of Russia’s Far East, as well as expand exports.

Source: TASS

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.